Merck & Co., Inc. MRK
i
Market dataready · fetched 2026-11-03T22:32:18.223Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-06
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T22:12:12.458297806Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-03T22:32:17.552751+00:00
Merck & Co., Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 149.20 | 39.0% | 3.5% | 140.11 | 43.4% | 3.6% |
| 25Δ | 148.26 | 38.4% | 3.0% | 140.99 | 44.0% | 3.2% |
| 30Δ | 147.52 | 39.0% | 2.6% | 141.84 | 43.8% | 2.7% |
| 35Δ | 146.84 | 39.7% | 2.3% | 142.63 | 43.6% | 2.4% |
| 40Δ | 146.10 | 38.7% | 2.0% | 143.40 | 42.2% | 2.0% |
| 45Δ | 145.44 | 38.0% | 1.7% | 144.16 | 40.7% | 1.6% |
| 50Δ | 144.80 | 37.4% | 1.4% | 144.84 | 43.1% | 1.5% |
| 55Δ | 144.19 | 37.2% | 1.2% | 145.56 | 43.8% | 1.3% |
| 60Δ | 143.60 | 36.4% | 1.0% | 146.28 | 43.4% | 1.1% |
| 65Δ | 143.02 | 35.3% | 0.8% | 146.99 | 42.5% | 0.9% |
| 70Δ | 142.34 | 35.7% | 0.7% | 148.25 | 48.6% | 0.8% |
| 75Δ | 141.40 | 38.6% | 0.6% | 149.29 | 49.2% | 0.6% |
| 80Δ | 140.61 | 38.5% | 0.4% | 150.80 | 51.9% | 0.5% |
20Δ
- Pseudo strike
- 149.20
- IV
- 39.0%
- B/E move
- 3.5%
- Pseudo strike
- 140.11
- IV
- 43.4%
- B/E move
- 3.6%
25Δ
- Pseudo strike
- 148.26
- IV
- 38.4%
- B/E move
- 3.0%
- Pseudo strike
- 140.99
- IV
- 44.0%
- B/E move
- 3.2%
30Δ
- Pseudo strike
- 147.52
- IV
- 39.0%
- B/E move
- 2.6%
- Pseudo strike
- 141.84
- IV
- 43.8%
- B/E move
- 2.7%
35Δ
- Pseudo strike
- 146.84
- IV
- 39.7%
- B/E move
- 2.3%
- Pseudo strike
- 142.63
- IV
- 43.6%
- B/E move
- 2.4%
40Δ
- Pseudo strike
- 146.10
- IV
- 38.7%
- B/E move
- 2.0%
- Pseudo strike
- 143.40
- IV
- 42.2%
- B/E move
- 2.0%
45Δ
- Pseudo strike
- 145.44
- IV
- 38.0%
- B/E move
- 1.7%
- Pseudo strike
- 144.16
- IV
- 40.7%
- B/E move
- 1.6%
50Δ
- Pseudo strike
- 144.80
- IV
- 37.4%
- B/E move
- 1.4%
- Pseudo strike
- 144.84
- IV
- 43.1%
- B/E move
- 1.5%
55Δ
- Pseudo strike
- 144.19
- IV
- 37.2%
- B/E move
- 1.2%
- Pseudo strike
- 145.56
- IV
- 43.8%
- B/E move
- 1.3%
60Δ
- Pseudo strike
- 143.60
- IV
- 36.4%
- B/E move
- 1.0%
- Pseudo strike
- 146.28
- IV
- 43.4%
- B/E move
- 1.1%
65Δ
- Pseudo strike
- 143.02
- IV
- 35.3%
- B/E move
- 0.8%
- Pseudo strike
- 146.99
- IV
- 42.5%
- B/E move
- 0.9%
70Δ
- Pseudo strike
- 142.34
- IV
- 35.7%
- B/E move
- 0.7%
- Pseudo strike
- 148.25
- IV
- 48.6%
- B/E move
- 0.8%
75Δ
- Pseudo strike
- 141.40
- IV
- 38.6%
- B/E move
- 0.6%
- Pseudo strike
- 149.29
- IV
- 49.2%
- B/E move
- 0.6%
80Δ
- Pseudo strike
- 140.61
- IV
- 38.5%
- B/E move
- 0.4%
- Pseudo strike
- 150.80
- IV
- 51.9%
- B/E move
- 0.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 34.52% | |
| 31.17% | |
| 24.77% | |
| 26.09% | |
| 25.20% | |
| 25.66% | |
| 29.22% | |
| 24.91% | |
| 28.81% | |
| 26.50% | |
| 42.07% | |
| 32.74% | |
| 28.11% | |
| 32.52% | |
| 31.46% | |
| 28.43% | |
| 28.10% | |
| 26.54% | |
| 27.05% | |
| 27.88% | |
| 27.52% | |
| 27.31% | |
| 27.08% | |
| 29.96% | |
| 29.64% | |
| 30.04% | |
| 27.20% | |
| 28.85% | |
| 28.78% | |
| 28.56% | |
| 28.24% | |
| 24.70% | |
| 27.26% | |
| 28.39% | |
| 29.46% | |
| 32.39% | |
| 28.52% | |
| 29.80% | |
| 28.65% | |
| 30.49% | |
| 29.06% | |
| 28.06% | |
| 30.00% | |
| 30.85% | |
| 30.33% | |
| 31.77% | |
| 32.74% | |
| 34.03% | |
| 35.06% | |
| 36.67% | |
| 39.39% | |
| 38.91% | |
| 40.28% | |
| 43.10% | |
| 42.45% | |
| 45.98% | |
| 39.70% | |
| 44.23% | |
| 43.98% | |
| 47.12% | |
| 35.32% | |
| 31.96% |
Drug Manufacturers - General
NVO
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in…
More →NVS
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
More →OGN
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine,…
More →PFE
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company…
More →SNY
Description unavailable
More →ABBV
Description unavailable
More →